164 related articles for article (PubMed ID: 36812669)
1. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications.
Wei Y; Zhang Y; Li P; Yan C; Wang L
Int Immunopharmacol; 2023 Apr; 117():109744. PubMed ID: 36812669
[TBL] [Abstract][Full Text] [Related]
2. Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice.
Beuth J; Schierholz JM; Mayer G
Cancer Lett; 2000 Oct; 159(1):9-13. PubMed ID: 10974400
[TBL] [Abstract][Full Text] [Related]
3. Thymalfasin: an immune system enhancer for the treatment of liver disease.
Sjogren MH
J Gastroenterol Hepatol; 2004 Dec; 19(12):S69-72. PubMed ID: 15641207
[TBL] [Abstract][Full Text] [Related]
4. From lab to bedside: emerging clinical applications of thymosin alpha 1.
Goldstein AL; Goldstein AL
Expert Opin Biol Ther; 2009 May; 9(5):593-608. PubMed ID: 19392576
[TBL] [Abstract][Full Text] [Related]
5. Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
Wei YT; Wang XR; Yan C; Huang F; Zhang Y; Liu X; Wen ZF; Sun XT; Zhang Y; Chen YQ; Gao R; Pan N; Wang LX
Cancer Res; 2022 May; 82(10):1991-2002. PubMed ID: 35364609
[TBL] [Abstract][Full Text] [Related]
6. Immune Modulation with Thymosin Alpha 1 Treatment.
King R; Tuthill C
Vitam Horm; 2016; 102():151-78. PubMed ID: 27450734
[TBL] [Abstract][Full Text] [Related]
7. Thymosin alpha-1 treatment in chronic hepatitis B.
Wu X; Jia J; You H
Expert Opin Biol Ther; 2015; 15 Suppl 1():S129-32. PubMed ID: 25640173
[TBL] [Abstract][Full Text] [Related]
8. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
Liaw YF
J Gastroenterol Hepatol; 2004 Dec; 19(12):S73-5. PubMed ID: 15641208
[TBL] [Abstract][Full Text] [Related]
9. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.
Garaci E; Pica F; Sinibaldi-Vallebona P; Pierimarchi P; Mastino A; Matteucci C; Rasi G
Int Immunopharmacol; 2003 Aug; 3(8):1145-50. PubMed ID: 12860169
[TBL] [Abstract][Full Text] [Related]
10. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.
Garaci E; Pica F; Rasi G; Favalli C
Int J Immunopharmacol; 2000 Dec; 22(12):1067-76. PubMed ID: 11137613
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal co-administration of thymosin alpha-1 ameliorates streptozotocin-induced pancreatic lesions and diabetes in C57BL/6 mice.
Qiu L; Zhang C; Zhang J; Liang J; Liu J; Ji C; Yang JY
Int J Mol Med; 2009 May; 23(5):597-602. PubMed ID: 19360317
[TBL] [Abstract][Full Text] [Related]
12. [Combination therapy of thymosin alpha1 and high dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura].
Wang L; Guo CS; Hou M; Li LZ; Zhang CQ; Chen F; Qin P; Peng J; He WD; Chu XX
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):274-6. PubMed ID: 17637261
[TBL] [Abstract][Full Text] [Related]
13. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Mao L
Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
[TBL] [Abstract][Full Text] [Related]
14. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.
Tomati V; Caci E; Ferrera L; Pesce E; Sondo E; Cholon DM; Quinney NL; Boyles SE; Armirotti A; Ravazzolo R; Galietta LJ; Gentzsch M; Pedemonte N
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415893
[TBL] [Abstract][Full Text] [Related]
15. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.
Andreone P; Gramenzi A; Cursaro C; Felline F; Loggi E; D'Errico A; Spinosa M; Lorenzini S; Biselli M; Bernardi M
J Viral Hepat; 2004 Jan; 11(1):69-73. PubMed ID: 14738560
[TBL] [Abstract][Full Text] [Related]
16. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.
Lau GK; Nanji A; Hou J; Fong DY; Au WS; Yuen ST; Lin M; Kung HF; Lam SK
J Viral Hepat; 2002 Jul; 9(4):280-7. PubMed ID: 12081605
[TBL] [Abstract][Full Text] [Related]
17. Thymalfasin: an immune system enhancer for the treatment of liver disease.
Sjogren MH
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S69-72. PubMed ID: 15546253
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of thymosin-alpha 1 therapy for chronic hepatitis D.
Zavaglia C; Bottelli R; Smedile A; Iamoni G; Mondazzi L; Airoldi A; Lanzani F; Idéo G
J Clin Gastroenterol; 1996 Sep; 23(2):162-3. PubMed ID: 8877652
[No Abstract] [Full Text] [Related]
19. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Jia Z; Feng Z; Tian R; Wang Q; Wang L
Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
[TBL] [Abstract][Full Text] [Related]
20. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
Zavaglia C; Severini R; Tinelli C; Franzone JS; Airoldi A; Tempini S; Bettale G; Ideo G
Dig Dis Sci; 2000 Apr; 45(4):690-6. PubMed ID: 10759236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
